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Abstract The clinical and epidemiological characteris-
tics of 111 consecutive cases of visceral leishmaniasis
identified from 1980 to 2000 in a Sicilian pediatric hos-
pital were analyzed retrospectively. The mean age of the
patients was 1.7 years. All children were HIV negative,
but 15% were severely malnourished. Fever and spleno-
megaly were present in all cases and hepatomegaly in
101 (90.1%) cases. Thrombocytopenia and anemia were
both observed in 78 (70.2%) cases and leukopenia in 47
(42.3%) cases. A bone marrow aspirate was obtained in
all cases; Leishmania amastigotes were detected in 89
(80.2%) cases. Initial treatment consisted of meglumine
antimoniate in 99 (89.2%) patients and amphotericin B
in 12 (10.8%) patients. Only two children treated with
meglumine antimoniate relapsed. The findings highlight
the differences between the cases of visceral leishmania-
sis observed in the Mediterranean basin and those ob-
served in other regions. The use of the term “Mediterra-
nean visceral leishmaniasis”, rather than the term “kala-
azar”, is proposed for cases observed in the Mediterra-
nean area.
Introduction
Visceral leishmaniasis (VL) is endemic in areas border-
ing the Mediterranean Sea (Spain, Italy, France, Greece,
Morocco, Tunisia), where it is caused by the protozoan
Leishmania infantum and is transmitted by the bite of he-
matophagous sandflies belonging to Phlebotomus spp.
The dog constitutes the proven reservoir of the infection.
Sicily is the largest island in the Mediterranean Sea. It
was recently estimated that approximately 47% of the Si-
cilian population live in areas at risk for Leishmania in-
fection, these areas consisting mainly of rural areas,
small villages, or peripheral districts of towns where the
vector sandfly species are more abundant. During the
1987–1995 period, the annual incidence of VL in the
general population was 6 cases per 1,000,000 residents
[1].
In comparison with the past, when VL was typically
observed more frequently in children, the current age-
related epidemiologic features observed in Sicily reflect
those reported for other Mediterranean regions of Eu-
rope, such as France, Spain, and Greece, where the ratio
of childhood to adult cases is approximately 1:1 [1, 2, 3].
Pentavalent antimonial drugs have been used for
many decades as standard treatment for VL [4]. They
have been used extensively in children and have been
demonstrated to be safe and effective. During the last de-
cade, the emergence of Leishmania strains resistant to
pentavalent antimonials and the occurrence of side ef-
fects have prompted the evaluation of other drugs, in-
cluding pentamidine and lipid formulations of amphoter-
icin B [4].
We analyzed retrospectively the epidemiologic, clini-
cal, and therapeutic features of 111 children affected by
VL and admitted consecutively to our hospital over a 21-
year period (1980–2000). This is the hospital where anti-
monial drugs were employed for the first time in the
therapy of VL, in the early part of the 20th century [5].
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Subjects and Methods
The G. Di Cristina Hospital in Palermo is the largest children’s
hospital in Sicily. It is a tertiary-care university hospital with 350
beds serving a population of about 1,000,000 in the Palermo dis-
trict; furthermore, it acts as referral pediatric center for all of west-
ern Sicily. In this study, the guidelines of the G. Di Cristina Hospi-
tal were followed in the conduct of clinical research.
All children aged 0–14 years diagnosed with VL consecutively
from January 1980 through December 2000 were included in the
study. The patient’s clinical histories were stored in a database that
included their demographic characteristics (age, sex), clinical and
laboratory findings recorded on admission and during hospitaliza-
tion, therapeutic interventions, and clinical outcome.
Diagnosis of VL was established if patients met at least one of
the following criteria: 
– Presence of clinical signs and symptoms compatible with VL
(fever, hepato-splenomegaly, pancytopenia, hypergammaglob-
ulinemia) and detection of serum Leishmania antibodies by an
immunofluorescent antibody test (IFAT) at a titer ≥1:40;
– Demonstration of the presence of Leishmania parasites in the
bone marrow or spleen aspirates by microscopy and/or culture.
Fever was defined as a temperature ≥38°C; anemia was defined as
a hemoglobin value of <9 mg/dl; leukopenia was defined as
<4,000 leukocytes/µl, and thrombocytopenia as <150,000 plate-
lets/µl.
Patients were treated with meglumine antimoniate (Glucantim;
Aventis Pharma, Italy) or with liposomal amphotericin B (L-
AmB) (AmBisome; Gilead, USA). Six of these patients had been
enrolled in clinical trials [6, 7, 8]. Meglumine antimoniate was ad-
ministered intramuscularly, generally for 21 days at a dosage of
560 mg/m2 of SbV after a gradually increasing daily dose during
the first 3–4 days of therapy. Other schedules such as a 28-day
course at a dosage of pentavalent antimony of 20/mg/kg/day, two
15-day courses separated by 10–15 days without therapy, and oth-
ers were adopted for patients enrolled in clinical trials or were
based on the individual physician’s preference. L-AmB was used
for patients enrolled in clinical trials and for patients that did not
respond to antimonial treatment or who experienced side effects or
relapse after antimonial therapy. L-AmB was administered intra-
venously at a dosage of 3 mg/kg for 10 consecutive days (total
dose, 30 mg/kg) or on days 1, 2, 3, 4, 5, and 10 (total dose, 
18 mg/kg) or on days 1, 2, 3, 4, and 10 (total dose, 15 mg/kg).
Clinical response was assessed at the completion of treatment
and was defined as cure (defervescence, restoration of laboratory
parameters, or reduction of spleen size) or failure (persistence or
worsening of clinical and laboratory findings). Relapse was de-
fined as the reappearance of signs and symptoms of disease in as-
sociation with identification of amastigote forms of Leishmania in
bone marrow smears after initial successful treatment. Most of the
patients were monitored at the outpatient clinic of the hospital for
at least 1 year after treatment was completed.
IFAT has been performed routinely since 1989 using a com-
mercial kit (Leishmania -Spot IF; bioMérieux, France). Cultures
were performed by seeding bone marrow aspirates into a semisol-
id blood-agar-based medium (Sloppy Evans medium) generously
supplied by Istituto Superiore di Sanità in Rome.
Positive cultures were sent to the Istituto Superiore di Sanità,
where Leishmania strains were characterized by Dr. M. Gramiccia
by means of starch electrophoretic analysis of 15 isoenzymes, us-
ing the techniques and zymodeme nomenclature of the World
Health Organization Collaborating Center (Montpellier, France).
Results
From January 1980 to December 2000, 111 children
were diagnosed with VL. Admissions averaged five per
year, without any seasonal variation. The patients’ medi-
an age was 1.7 years (range, 4.5 months–11.7 years); 19
(17.1%) patients were aged <12 months. Fifty-six
(50.4%) were males. No child was HIV positive. Analy-
sis of the nutritional status of the patients showed that 17
(15.3%) were below the tenth percentile on the weight-
for-age growth chart. Two (1.8%) patients had an under-
lying disease at hospital admission: one was affected by
Wilson’s disease, the other one by pseudomembranous
conjunctivitis. Twenty-five (22.5%) patients had a con-
current bacterial or viral infection, including acute otitis
media (7 patients), respiratory infections (8 patients, up-
per respiratory infection; 5 patients, bronchitis; and 3 pa-
tients, pneumonia), and tonsillitis (2 patients). One girl
was an immigrant from Ghana. In all but one case, the
disease was contracted in western Sicily. Eighty-nine
(80%) patients lived in districts that were located near
the foothills of mountains bordering the city or within
the city itself. The median time from the onset of symp-
toms to hospital admission was 15 days (range, 2 days–
7 months). Fever and splenomegaly were present at ad-
mission in all patients (Table 1). 
Interestingly, in two cases a small skin lesion on the
face was associated with VL and preceded the onset of
full-blown disease. In both cases numerous intracellular
and extracellular Leishmania amastigotes were present
on the smears obtained from the lesions (Fig. 1a). 
The most frequently encountered hematological find-
ings were thrombocytopenia and anemia, both of which
were observed in 80.4% of the patients. Leukopenia was
found in 43.1% of the patients, and <500 neutrophils
were present in 9.1% of the patients. Pancytopenia was
present in six (5.7%) patients, and both leukopenia and
thrombocytopenia without anemia in 28 (26.9%) pa-
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Table 1 Clinical features of
111 children with visceral
leishmaniasis
Clinical feature Finding
Median duration of disease before admission (range) 15 days (2 days–7 months)
Fever [no. of cases (%)] 111 (100)
Splenomegaly [no. of cases (%)] 111 (100)
Extent of spleen enlargement [median distance below 4 cm (2–13 cm)
left costal margin (range)]
Hepatomegaly [no. of cases (%)] 101 (91)
Extent of liver enlargement [median distance below 3 cm (0–11 cm)
the right costal margin (range)]
Skin lesions (no. of cases) 2
Lymphadenopathy (no. of cases)a 0
a Mild enlargement of the small
lymph nodes in the cervical
chain of 13 patients was not
considered true lymphadenopa-
thy related to visceral leishma-
niasis
tients. Fifteen (13.5%) patients required blood transfu-
sion due to anemia. The albumin value was <3 g/dl in
31.1% of the patients. In 22.4% of the patients, the albu-
min value was higher than the globulin value (albu-
min/globulin inversion). A value of aspartate amino-
transferase and of alanine aminotransferase >80 IU/l was
reported in 33.3% and 23.6%, respectively (Table 2). 
A bone marrow aspirate was obtained from all pa-
tients, and Leishmania amastigotes were detected in 89
(80.2%) cases. In one case, after two negative examina-
tions of bone marrow, a splenic aspirate was obtained; ex-
amination revealed Leishmania parasites. Culture from
bone marrow aspirate was performed in 41 cases and was
positive in 31 (75.6%). Leishmania infantum isolates
were isoenzymatically characterized: the zymodemes
identified were MON 1 in 24 cases and MON 27 and
MON 80 in 1 case each. The remaining five strains could
not be characterized due to bacterial contamination.
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Fig. 1 a Small, reddish macula observed on the face of a child
with visceral leishmaniasis caused by a viscerotropic strain
(MON1) of Leishmania infantum. Inset: Giemsa-stained smear
showing intracellular and extracellular Leishmania amastigotes
(original magnification, ×1000) b Typical presentation of Old
World cutaneous leishmaniasis (oriental sore, caused by a dermo-
tropic strain of Leishmania infantum) in the Sicilian region
Table 2 Hematological and biochemical features of 111 children
with visceral leishmaniasis
Variable Median value (range)
Erythrocyte count (×106 cells/µl) 3.7 (1.9–5)
Hemoglobin (g/dl) 7.8 (3.8–12.7)
Leukocyte count (×103 cells/µl) 4.3 (1.6–10.9)
Neutrophil count (×103 cells/µl) 1 (0.2–3.7)
Platelets (×103 cells/µl) 110 (12–362)
Erythrocyte sedimentation rate (mm/h) 73 (9–138)
C-reactive protein (mg/100 ml) 2.3 (0.3–18.2)
Total protein (g/dl) 7.3 (4.5–10.4)
Albumin (g/dl) 3.3 (1.4–5.3)
Gammaglobulin (g/dl) 2.3 (0.6–6.6)
Aspartate aminotransferase (IU/l) 53 (19–847)
Alanine aminotransferase (IU/l) 33 (8–497)
IFAT was performed in 84 (75.7%) cases; it gave a
false-negative result in only 2 cases (in these cases, the
diagnosis was made by microscopy). The geometric
mean titer of anti-Leishmania antibody was 227 (range,
0–5,120).
Diagnosis of visceral leishmaniasis was established by
direct microscopy of bone marrow together with positive
IFAT in 60 patients; by means of IFAT alone in 22 (in 1
of these, diagnosis was confirmed by a positive culture),
and by microscopy alone in 29. Diagnosis was made a
median of 2 days (range, 0–23 days) after admission.
Ninety-nine (89.2%) patients were treated initially
with meglumine antimoniate and 12 (10.8%) patients
with L-AmB. Patients were followed-up at the outpatient
clinic for a median of 1 year (range, 6 months–3 years)
after treatment was completed. Of the 99 patients treated
with meglumine antimoniate, 1 was still febrile after 
6 days, so treatment was switched to L-AmB. Two pa-
tients relapsed within the next 100 days and then were
treated with L-AmB; one had been treated with 
20 mg/kg for 28 days, the other one with 25 mg/kg per
30 days in two 15-day courses. Of the patients treated
with L-AmB, one had been treated for VL with meglu-
mine antimoniate 1 year previously in another part of 
Italy (Ancona). This case should be considered a relapse.
All patients treated with L-AmB recovered, and none re-
lapsed (Table 3). The cutaneous lesion (Fig. 1a) associat-
ed with a case of VL persisted after six doses (on day
10) of L-AmB, even though it became slightly less red-
dish than observed initially. Scarce amastigotes were still
present on the smear, so a 10-day course of intralesional
meglumine antimoniate (about 20 mg of SbV, given on
alternate days) was administered, which resulted in com-
plete resolution of the skin lesion. 
Adverse effects while receiving meglumine antimoni-
ate were observed in 16 patients, including rash (3 pa-
tients) and dry cough (13 patients). All adverse effects
but one (the severe urticarial rash) were transient and
self-limited and did not require interruption of treatment.
No adverse effects were detected in the 16 patients treat-
ed with L-AmB (only a transient rash on day 9 of thera-
py, possibly not related to therapy).
A reduction of spleen size up to half of the size ini-
tially palpated was observed a median of 10 days (range,
4–28 days) after treatment was begun. Overall, patients
became afebrile a median of 4 days (range, 1–9 days) af-
ter treatment was initiated, whereas hematological resto-
ration occurred a median of 12 days later (range, 9–30
days).
Twelve patients developed nosocomial infections:
gastroenteritis (5 patients, caused by rotavirus in 3),
chickenpox (1 patient), measles (1 patient), urinary tract
infection (1 patient), and maculopapular exanthema
caused by infection with human herpesvirus 6 (4 pa-
tients).
Discussion
The different forms of cutaneous leishmaniasis (i.e., cu-
taneous leishmaniasis, diffuse cutaneous leishmaniasis,
and mucocutaneous leishmaniasis) are classified accord-
ing to their epidemiology and clinical presentation [9].
Although VL acquired in the Mediterranean area has a
different epidemiology and clinical presentation than that
acquired in India or in other regions, all forms of VL are
generally still referred to using the Hindi term “kala-
azar”, even in the latest edition of the two major text-
books of infectious and tropical diseases [9, 10]. Never-
theless, there are many differences between the disease
acquired in the Mediterranean basin and other forms
contracted elsewhere. These include the Leishmania spe-
cies involved, the lack of post kala-azar dermal leishma-
niasis, and the absence of skin hyperpigmentation 
(Table 4). Therefore, we believe that the term “kala-
azar” and VL should not be used interchangeably for
cases observed in the Mediterranean basin. 
As in other case series describing VL acquired in the
Mediterranean area [13, 14, 15], VL in Sicily involved
mainly young children: the median age of our patients
was 1.7 years, and 26.1% of the children were younger
than 12 months. The main clinical and laboratory find-
ings were also similar to those reported in the other
Mediterranean countries [13, 14, 15].
A critical issue we would like to highlight is the ap-
pearance of lymphadenopathy during the course of VL;
this is probably a quite common feature in Sudan (84%)
[16, 17], but it is rarer in the Mediterranean basin
(36–39%) [13, 14]. Furthermore, in our experience, ex-
cept for lymphadenopathy of the small posterior cervical
lymph nodes, which is a very common but nonspecific
finding among children 2–14 years of age, lymphaden-
opathy was not found in any case. It would be very use-
ful to know if, in the more recently reported pediatric se-
ries from the Mediterranean basin [13, 14], the finding of
lymphadenopathy was definitely correlated to VL or, as
we suppose, it was an occasional finding unrelated to the
disease. In the future, we suggest that authors describing
VL report the entity and the sites involved in the case of
lymphadenopathy.
In contrast to what was reported in the last edition of
the Mandell textbook [9], i.e., that “the presence of a
hard spleen suggests a hematologic disorder or other di-
agnosis such as schistosomiasis”, the spleen was hard in
almost all of our patients. In fact, on the basis of the
above misleading information, several of our patients
were initially admitted to the hematologic department.
In two cases we observed a small, noninfiltrated le-
sion on the skin in which many Leishmania amastigotes
were seen by microscopy. This kind of lesion preceding
VL must be differentiated from the lesions of the typical
cutaneous leishmaniasis that occurs in our region
(known as “oriental sore” or dry form), which is caused
by dermotropic strains of Leishmania infantum. It
presents as a firm, painless, slow-growing, infiltrated
papule and forms a well-circumscribed central ulceration
with very few amastigotes (Fig. 1b) [18]. To the best of
our knowledge, there are only two previous reports of
skin involvement preceding overt VL in the Mediterra-
nean area [19, 20].
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Table 3 Treatment and outcome of the 111 children with visceral leishmaniasis
Drug and dosage Duration of therapy No. of courses of therapy No. of Clinical No. of 
cases response relapses
Meglumine antimoniate; <18 days (median, 14.5; 1 course, n=19 patients; 21 19/21a 0
median SbV 23.5 mg/kg/day range, 2–17) 2 courses, n=2 patients
(range, 14–30.2 mg/kg/day) 18–24 days (median, 21; 1 course, n=50 patients; 65 65/65 0
range, 18–24) 2 courses, n=15 patients
>24 days (median, 28; 1 course, n=8 patients; 13 13/13 2/13
range, 25–30) 2 courses, n=5 patients
Liposomal AmB; 5 days (4+1 on day 10) 2 2/2 0
3 mg/kg/day 6 days (5+1 on day 10) 11b 11/11 0
10 days 3c 3/3 0
a Two patients were switched from meglumine antimoniate to lipo-
somal amphotericin B: 1 on day 6 of meglumine antimoniate treat-
ment because clinical and laboratory findings had worsened, and 1
because of adverse reaction to meglumine antimoniate (severe ur-
ticarial rash after the second dose)
b Includes the two cases described above in footnote “a”
c Includes the two cases that relapsed after antimonial therapy
Table 4 Characteristic of the four forms of visceral leishmaniasis observed worldwide in otherwise immunocompetent patients
Characteristic Mediterranean American Kala-azar African kala-azar
visceral visceral 
leishmaniasis leishmaniasis
Main geographical Mediterranean basin northeast Brazil, India, Pakistan, Nepal, Sudan, Kenya, 
area Central America northern and southern China Horn of Africa
Epidemiology endemic endemic endemic/epidemic endemic/epidemic
Cycle zooanthroponosisa zooanthroponosis anthroponosis zooanthroponosis/
anthroponosis?
Reservoir dogs, foxes, jackals dogs, foxes, opossums humans rodents? dogs? humans?
Causative L. donovani infantum L. donovani chagasib L. donovani donovani L. donovani donovani
Leishmania species
Vector species Phlebotomus perniciosus, Lutzomyia longipalpis; Phlebotomus argentipes; Phlebotomus orientalis, 
and natural habitat Phlebotomus. ariasi; rural, peridomestic rural Phlebotomus martini; rural
domestic
Male/female ratio 1:1 male>female 6:1 ?
Age of patients <5 yearsc young children young adults young adults?
usually affected
Clinical manifestations
Fever 95–100% 95–100% 95–100% 95–100%
Splenomegaly 95–100% 95–100% 95–100% 95–100%
Hepatomegaly ~70% ~70% ~75% ~75%
Skin no no 70% yes
hyperpigmentation
Lymphadenopathy 0–39% ? 5% 84%
Occurrence of no no 6–20%; <2 years up to 2–5%; shortly after 
post-kala-azar dermal 20 years after initial treatment
leishmaniasis infection
Resistance to rare rare frequent frequent
antimonial agents
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We believe that at least a proportion of cases of VL
among children are preceded by a very small lesion, gen-
erally considered a banal mosquito bite (even if it lasts
for a longer time), and it would be useful in the future to
investigate this point and to accurately examine the skin
of VL patients.
As far as therapy of VL is concerned, pentavalent an-
timonials are still indicated as the drug of choice due to
their availability, low cost, and efficacy. Although it is
not feasible to make direct comparisons between the
treatment regimens due to several possible selection bi-
ases, we found that a 21-day course of meglumine anti-
moniate 560 mg/m2/day (of SbV) (22.4–26.6 mg/kg/day),
gradually increasing the daily dose during the first 3–4
days of therapy, is at least as effective as two 15-day
courses or a 28-day course with 20 mg of SbV (the WHO
recommended treatment) [2]. Resistance to pentavalent
antimonials has been documented in India and Sudan
[4], although it does not seem to be a problem in our re-
gion; we did, however, observe two relapses.
A 6-day course (on days 1–5 and 10) of therapy with
L-AmB was shown to be effective and safe in children
with VL. The cost of this regimen for a 15 kg child in
our hospital is about $900, while the cost of a 21-day
course of meglumine antimoniate (25 mg/kg/day of SbV)
for the same child is $10; however, taking into account
the length of hospitalization (with a cost of $150 per
day) and the risk of acquiring nosocomial infections, in
our opinion the balance seems to favor the use of 
L-AmB as a first choice for the treatment of children
with VL in industrialized Mediterranean countries. In
this regard, we disagree with the recent Greek recom-
mendation [14], since we do not believe that the outpa-
tient administration of antimonials is feasible due to the
potential fatal toxicities of these drugs.
Unfortunately, meglumine antimoniate is currently
the only drug approved in Italy for the treatment of VL.
However, a multicenter randomized controlled trial (me-
glumine antimoniate vs. L-AmB) is now under way in 
Italy in which a pharmaco-economic evaluation also will
be performed.
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